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Abstract
Background: Chronic migraine is a chronic medical condition associated with resistance to pharmacological
treatment and poor benefits from the psychological interventions studied to date, including acceptance and
commitment therapy or mindfulness. This manuscript describes the rationale and methods for a pilot feasibility
study designed to (1) establish and (2) evaluate the feasibility and acceptability of research procedures and
interventions to investigate whether well-being therapy improves outcomes relative to a control condition.
Methods: The current intervention will use a randomized controlled trial design, wherein 30 outpatients with
chronic migraine will be randomized (1:1) to well-being therapy (n = 15) or to a control condition (n = 15). Primary
outcomes include the level of disability caused by migraine and the frequency, duration, and intensity of migraine
attacks; the secondary outcomes focus on anxiety, depression, psychological well-being, euthymia, and distress. Primary
and secondary outcomes will be assessed at baseline, after sessions 4 and 8, and at 3-month follow-up. The Ethical
Review Boards at the University-Hospital Careggi has approved the study (5th December 2017).
Discussion: Identifying medium-term interventions able to improve chronic migraine is relevant to manage this illness.
The present randomized trial might represent a step forward for managing chronic migraine by means of psychological
interventions.
Trial registration: ClinicalTrial.gov Identifier: NCT03404336. Registered on 19 January 2018.
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Background
Migraine is a prevalent disabling condition affecting ap-
proximately 15% of subjects in the general population
[1]. Migraine can be episodic (i.e., less than 15 headache
days per month) or chronic (15 or more headache days
per month for at least 3 months) [2–5], the latter affect-
ing 1–3% of the general population [6]. Chronic mi-
graine is the most disabling form of migraine, resulting
in lower socioeconomic status and health-related quality
of life as well as increased headache-related burden [6].
Chronic migraine is often resistant to treatment [7] and
the efficacy of stress-oriented psychotherapeutic inter-
ventions, such as acceptance and commitment therapy
and mindfulness, has been shown to be poor [8–18].
Well-being therapy (WBT) is a short-term (i.e., 8 ses-
sions) well-being-oriented psychotherapeutic strategy em-
phasizing self-observation of patient’s well-being with the
use of a structured diary, interaction between patients and
therapists, and homework [19–21]. It is based on the
model of psychological well-being developed by Jahoda in
1958 [22] and further refined by Ryff [23]. The goals of
WBT are the improvement of the psychological well-being
and the achievement of a state of euthymia [19–21]. In
previous randomized controlled trials, WBT was found to
be efficacious in reducing relapse rates in depressed adults
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[24, 25] and in treating generalized anxiety disorder [26]
and cyclothymia [27], suggesting that psychological well-
being may be increased by a specific psychotherapeutic
method and that such increase may yield a protective and
preventive effect. WBT was also shown to be efficacious
when distress-oriented psychotherapeutic interventions
did not produce benefits [28].
We designed a pilot study to (1) establish and (2) evalu-
ate the feasibility and acceptability of research procedures
and interventions to investigate whether WBT improves
outcomes relative to a control condition in chronic mi-
graine patients who were resistant to pharmacological
treatment. Although WBT might be a complementary
therapeutic option [29], no studies have addressed the po-
tential of such psychological intervention for chronic mi-
graine. The present manuscript describes the study design
and procedures for a pilot randomized controlled trial in-
vestigating feasibility, acceptability, and effects of WBT in
chronic migraine patients.
Methods
This protocol is reported in accordance to the Stand-
ard Protocol Items: Recommendation for Intervention
(SPIRIT) guidelines [30, 31]. For the SPIRIT Check-
list, see Additional file 1.
Study overview
This is a 16-week, stage 1b, single site study designed to
evaluate the feasibility, acceptability, and preliminary ef-
fects of two psychological interventions in chronic mi-
graine patients. It was designed to evaluate the feasibility
of conducting a two-arm pilot randomized controlled
trial with participants randomized (1:1) to WBT or to a
control condition. Primary and secondary outcomes will
be assessed at baseline, after sessions 4 and 8, and at
3-month follow-up. Figure 1 provides an overview of the
study design and timeline.
Specific aims
The specific aims and hypotheses for this pilot trial are (1)
to examine, from baseline to 3 month follow-up, the level
of disability due to migraine and the frequency, duration,
and intensity of migraine attacks. We hypothesize that pa-
tients receiving WBT will show a better outcome com-
pared to those assigned to the control condition (primary
outcome); and (2) to examine, from baseline to 3 month
follow-up, the level of anxiety, depression, psychological
Fig. 1 Summary of study timeline. PT post treatment assessment, 3 M 3-month follow-up
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well-being, euthymia, and distress. We hypothesize that
patients receiving WBT will show lower anxiety, depres-
sion, and distress, and greater psychological well-being
compared to those assigned to the control condition (sec-
ondary outcome).
Participant selection recruitment and retention
Eligibility criteria for this ongoing pilot trial (target n =
30) include (1) 18–65 years of age; (2) Italian mother
tongue; (3) a diagnosis of chronic migraine according to
the International Classification of Headache Disorders
[2], thus presenting specific features (i.e., unilateral and
pulsating pain of moderate or severe intensity, which is
aggravated or precipitated by routine physical activities
and is combined with nausea and/or vomiting, photo-
phobia, and phonophobia) and migraine headache on
15 or more days per month; (4) headache chronicity for
a minimum of 1 year and pattern of headache symptoms
stable for a period of at least 6 months [32]; (5) no
pharmacological therapy or dietary supplement use for
chronic migraine or pharmacological therapy/dietary
supplement use for chronic migraine stable for at least
3 months; and (6) psychotropic medication allowed only
if stable for at least 3 months.
Exclusion criteria are (1) a diagnosis of headaches due to
medication overuse; (2) co-occurrence of psychiatric disor-
der(s) according to the Diagnostic and Statistical Manual of
mental disorders 5th edition (DSM-5) [33], as diagnosed
via the MINI International Neuropsychiatric Interview [34];
(3) co-occurrence of chronic unstable medical conditions
[32]; (4) being pregnant or lactating [32]; (5) under exoge-
neous hormone treatment (i.e., hormonal contraceptives,
postmenopausal hormone therapy) [32]; or (6) any other
condition that, according to the investigators’ opinion, may
alter the ability of the patient to follow study procedures.
Participants will be recruited from the SOD Headache
Centre and Pharmacologic Clinic of the Careggi Univer-
sity Hospital of Florence. Research assistants (RAs) will
screen participants for preliminary eligibility and those
who meet initial eligibility criteria will be asked to attend
the clinic for an in-person evaluation where informed
consent is obtained. The current study employs several
measures to minimize attrition. All participants will be
assessed by clinical psychologists who will collect socio-
demographic and clinical data.
Randomization
Following eligibility determination, participants will be
randomly assigned to either WBT or a control condi-
tion. Block randomization of size two will be used. The
two groups will be balanced for age, sex, education, and
headache severity. The allocation schedule has been
created by the principal investigator (FC) using a com-
puterized random number generator and is concealed
to the investigators responsible for enrollment. When a
registered patient is randomized, the investigator will
contact the principal investigator who will communi-
cate the assigned treatment group. Single blindness will
be ensured.
Study interventions
Figure 2 provides an overview of the study procedure.
Fig. 2 Two-arm randomized controlled trial design and data collection schedule
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Well-being therapy (WBT)
WBT is used as the only non-pharmacological therapeutic
strategy. Eight sessions (Table 1) will be delivered every
other week, with a duration of 60 min each. The manua-
lized WBT will be used [19–21]. The initial phase is con-
cerned with self-observation of psychological well-being.
Once the instance of well-being is properly recognized,
the patient is encouraged to identify thoughts, beliefs, and
behaviors leading to premature interruption of well-being
(intermediate phase). The final part involves cognitive re-
structuring of dysfunctional dimensions of psychological
well-being and meeting the challenge that optimal experi-
ences may entail [19–21]. An assessment of treatment ad-
herence, satisfaction, and side effects will be performed via
ad hoc questions.
Control condition
The control condition will include 8 bi-weekly sessions
based on the Lifestyle and Well-being National Institute for
Health and Care Excellence (NICE) guidelines (https://
www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on
the World Health Organization 12 Steps to Healthy Eating
(http://www.euro.who.int/en/health-topics/disease-preven-
tion/nutrition/a-healthy-lifestyle). These sessions (Table 2)
will inform participants about well-being and the lifestyles
that can influence it. No access to specific WBT ingredients
will be allowed. An assessment of treatment adherence, sat-
isfaction, and side effects will be performed via ad hoc
questions.
Monitoring
The subjects will fill in the headache self-report daily
diary from 2 weeks before the first session of therapy.
Thereafter, they will receive the WBT or the control
intervention. The subjects will be re-assessed at the end
of session 4 of treatment, at the end of session 8 of treat-
ment, and at 3-month follow-up. Since participants will
not be informed if they receive WBT or the control con-
dition, an assessment of treatment credibility will be
provided at the end of session 8. At the conclusion of
the study, participants will be debriefed and informed
that the control condition was necessary to test the
study hypothesis.
Assessments
Measures selected in this study mirror those commonly
used in treatment outcome trials for chronic migraine [9,
13, 15, 16] and are consistent with the international expert
consensus guidelines for determining treatment response
[35, 36]. These measures include those for screening and
eligibility, assessing feasibility, acceptability and patient sat-
isfaction, monitoring patient safety, and determining pri-
mary and secondary clinical outcomes. Unless otherwise
specified, all measures, including primary and secondary
outcome measures, will be administered and collected by
Ph.D. level independent evaluators (IEs) naive to study
condition.
Eligibility determination and diagnostic assessment
The diagnosis of chronic migraine will be assessed for
the determination of eligibility by the clinical interview
according to the International Classification of Head-
ache Disorders [2]. Information on psychological and
pharmacological treatment history and co-occurrence
of chronic unstable medical conditions will be collected
via ad hoc questions previously used [37]. The co-oc-
currence of psychiatric disorders will be assessed via
the MINI International Neuropsychiatric Interview
[34], a short structured diagnostic interview validated
against the Structured Clinical Interview for DSM diag-
noses and against the Composite International Diag-
nostic Interview for ICD diagnoses as well as against
expert opinion in a large sample in four European
countries (France, United Kingdom, Italy, and Spain).
We will use the Italian version 7.0.0, which allows diag-
nosis formulation according to the DSM-5 [33].
Migraine and headache assessment
The level of pain and disability caused by migraines in
the patient’s life will be measured using the Migraine
Disability Assessment Score questionnaire [38, 39], a
5-item self-administered questionnaire evaluating the in-
fluence of migraine on three domains of activity, namely
paid work or school, household work, and family, social
or leisure activities, over the preceding 3 months; higher
scores indicate more severe disability. The Migraine Dis-
ability Assessment Score questionnaire showed good in-
ternal consistency and high reliability [39]. The level of
headache experienced will be assessed via a daily
self-report headache diary built according to the guide-
lines provided by Penzien et al. [32] for trials of behav-
ioral treatments for headache and according to the
guidelines provided by Tfelt-Hansen et al. [36] for con-
trolled trials of drugs in migraine treatment. The diary
collects information on headache frequency, average
headache severity (0 = no headache, 1 =mild headache,
2 =moderate headache, 3 = severe headache), duration of
peak headache in hours (start time, end time), intake of
symptomatic headache treatments (dose), headache relief
after 2 h (0 = no headache, 1 =mild headache, 2 =mod-
erate headache, 3 = severe headache), functional disabil-
ity for the day scale (0 = no disability: able to function
normally; 1 = performance of daily activities mildly im-
paired: can still do everything but with difficulties; 2 =
performance of daily activities moderately impaired: un-
able to do some things; 3 = performance of daily activ-
ities severely impaired: cannot do all or most things, bed
rest may be necessary).
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Table 1 Well-being therapy (WBT) sessions according to Fava [19, 21] and Fava et al. [20]
Session Focus Objectives Tool
Session 1 Identifying and setting episodes of
well-being into situational context
Report the circumstances surrounding the episodes of well-being rated on a
scale of 0 to 100, with zero being absence of well-being and 100 being the
most intense well-being
Diary
Session 2 Optimal experiences Define optimal experiences and report on them Diary
Session 3 Identifying interfering thoughts
and behaviors
Report the thoughts and behaviors that interrupt well-being Diary
Session 4 Illustrating autonomy Proposing the dimension of autonomy as material for reflections to the
well-being diary
Examples,
metaphors
Reflecting and practicing
autonomy
Attempting to explain the premature interruption of well-being with the help
of the dimension of autonomy
Daily exposure to
pleasurable activities
and diary
Session 5 Illustrating environmental mastery Proposing the dimension of environmental mastery as material for reflections
to the well-being diary
Examples,
metaphors
Reflecting and practicing
environmental mastery
Attempting to explain the premature interruption of well-being with the help
of the dimension of environmental mastery
Daily exposure to
pleasurable activities
and diary
Session 6 Illustrating positive relations with
others
Proposing the dimension of satisfactory interactions as material for reflections
to the well-being diary
Examples,
metaphors
Reflecting and practicing positive
relations with others
Attempting to explain the premature interruption of well-being with the help
of the dimension of satisfactory interactions
Daily exposure to
pleasurable activities
and diary
Illustrating personal growth Proposing the dimension of individual’s style and degree of growth as material
for reflections to the well-being diary
Examples,
metaphors
Reflecting and practicing personal
growth
Attempting to explain the premature interruption of well-being with the help
of the dimension of individual’s style and degree of growth
Daily exposure to
pleasurable activities
+ diary
Session 7 Illustrating self-acceptance Proposing the dimension of development or self-actualization as material for
reflections to the well-being diary
Examples,
metaphors
Reflecting and practicing
self-acceptance
Attempting to explain the premature interruption of well-being with the help
of the dimension of development or self-actualization
Daily exposure to
pleasurable activities
and diary
Illustrating purpose in life Proposing the dimension of an individual’s balance and integration of psychic
forces as material for reflections to the well-being diary
Examples,
metaphors
Reflecting and practicing purpose
in life
Attempting to explain the premature interruption of well-being with the help
of the dimension of an individual’s balance and integration of psychic forces
Daily exposure to
pleasurable activities
and diary
Session 8 Placing the experience of WBT in
the treatment history of the
patient
Ending treatment therapy
Review the patient’s effort to contrast interruptions of well-being
Continuing cognitive restructuring and in vivo contrast of automatic thoughts
Checking the patient’s feeling about ending the therapy
Diary
Table 2 Control condition according to the NICE guidelines [34] and World Health Organization-12 Steps to Healthy Eating (http://
www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle)
Sessions Focus
Session 1 Illustrating the concept of lifestyle and well-being
Session 2 Illustrating healthy eating and steps to healthy eating
Session 3
Session 4 Illustrating physical exercise and how it promotes health
Session 5 Illustrating smoking and tobacco and how they can damage health
Session 6 Illustrating alcohol and how it can damage health
Session 7 Illustrating drug misuse and how it can damage health
Session 8 Illustrating sexual health
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Feasibility, acceptability, and participant satisfaction
Measures of feasibility include the ability to recruit the
intended population from the SOD Headache Centre
and Pharmacologic Clinic of the University Hospital
Careggi of Florence, participant willingness to be ran-
domized, and session attendance. In addition, the widely
used Client Satisfaction Questionnaire-8 [40] is pro-
posed. The credibility of treatment rationale and expect-
ancy for improvement are evaluated via the Credibility
Expectancy Questionnaire [41], which has been shown
to be predictive of clinical outcomes in previous treat-
ment trials and was adapted to include questions on ex-
pectancies regarding the likelihood of reduction of
headache symptoms.
To maintain the blindness of the IEs, these acceptabil-
ity and satisfaction measures will be administered at the
end of the treatment period (session 8) by RAs not
otherwise involved in the study.
Primary outcomes
The level of disability caused by migraine and the fre-
quency, duration, and intensity of migraine attacks are
the primary clinical outcomes, measured at baseline
(prior to randomization), at the end of sessions 4 and 8
of the treatment, and at 3-month follow-up.
Secondary outcomes
Secondary outcomes focus on anxiety, depression, psycho-
logical well-being, euthymia, and distress. These variables
are assessed at baseline (prior to randomization), at the end
of session 4 and 8 of the treatment, and at 3-month
follow-up. Anxiety and depression will be assessed via the
Symptom Questionnaire [42, 43], a self-administered
92-item dichotomous scale (yes/no or true/false), of which
68 items indicate symptoms (symptom subscales) and 24
items are antonyms of some of the symptoms and indicate
well-being (well-being subscale). Higher subscale scores in-
dicate higher severity of symptoms or higher well-being, re-
spectively. The Symptom Questionnaire had good validity
and reliability [43]. Psychological well-being will be
assessed via (1) the World Health Organization-Five Well-
Being Index [44], a self-administered 5-item scale, with an-
swers rated on a 6-point Likert scale assessing well-being
in the 2 previous weeks, wherein the higher the score, the
higher the level of well-being; and (2) the Psychological
Well-Being Questionnaire [45], a 84-item self-administered
inventory, rated on a 6-point Likert scale, measuring six
constructs, namely Autonomy (i.e., independence and
self-determination); Environmental Mastery (i.e., ability to
manage one’s life); Personal Growth (i.e., being open to
new experiences); Positive Relations with others (i.e., having
satisfying relationships); Purpose in Life (i.e., believing that
one’s life is meaningful); and Self-Acceptance (i.e., having a
positive attitude towards oneself and past life). The
Psychological Well-Being Questionnaire has shown good
psychometric properties [46].
Euthymia will be assessed via the Euthymia scale [47],
a self-administered scale consisting of 10 items with a
dichotomous response mode (yes/no or true/false). The
higher the score, the higher the level of euthymia [47].
Distress will be measured via the Psychosocial Index
[48], a 55-item questionnaire assessing stress, wellness,
illness behavior, psychological distress, and quality of life;
it showed good psychometric properties [49]. Some
questions of the Psychosocial Index require specific re-
sponses, most of them provide a dichotomous response,
others are measured on a 4-point Likert scale. The final
item, on the quality of life, has five possible answers.
Assessment training
All IEs are Ph.D.-level researchers with extensive prior
diagnostic assessment experience. Regardless of familiarity
with study assessment measures, all IEs will receive add-
itional training on the primary and secondary clinical out-
come measures prior to conducting study assessments.
This includes training on viewing and rating clinical out-
come measures, created by the principal investigator (FC).
RAs will follow our standard training protocol under the
direction of the study investigators. This structured train-
ing protocol consists of a graduated set of tasks and expe-
riences, beginning with reading relevant papers, studying
instruments and instruction booklets, multi-day didactics,
and reviewing suggestions for handling common inter-
viewing problems. RAs are closely supervised during these
training sessions and during their initial interviews by the
principal investigator (FC).
Data management and statistical analysis plan
Data collection, management and assurance of quality
Data from the self-report questionnaires, self-report
headache diary, and the MINI will be first recorded on
paper forms and then entered into the SPSS 20.0 (Statis-
tical Package for Social Science) [50] macro and verified
by research staff. Several data monitoring procedures
will be implemented to ensure data quality, including (1)
systematically recording study notes-to-file in the case of
any event that threatens data integrity and (2) routine
internal audits confirming proper informed consent, ac-
curate completion of data forms, and documentation of
missing data.
Data analysis plan
We will primarily focus on descriptive statistics to exam-
ine both feasibility, acceptability, and outcomes. This in-
cludes examining rates of study recruitment, participant’s
willingness to be randomized, session attendance, and pa-
tient satisfaction. Additionally, we will compare rates of
migraine attacks per month and their duration as well as
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the level of disability due to migraine and psychological
measures. We will also examine the means of key variables
(i.e., level of pain and disability caused by migraine,
frequency, duration, and intensity of migraine attacks, anx-
iety, depression, psychological well-being, euthymia, dis-
tress) across baseline, session 4, session 8, and 3-month
follow-up. We will use ANCOVA to compare means of
variables [51], χ2 to compare frequencies, and a multivariate
logistic regression analyses to identify independent predic-
tors of psychological well-being among socio-demographic
and psychological variables measured at baseline. The
number of migraine attacks are recorded via the headache
self-report daily diary following the rules suggested by
Tfelt-Hansen et al. [36], namely (1) a migraine attack which
is interrupted by sleep, or temporarily remits, and then re-
curs within 48 h is recorded as one attack; (2) an attack
treated successfully with medication but with relapse within
48 h counts as one attack; and (3) a practical solution to
differing these using diary entries over the previous month
is to count as distinct attacks only those that are separated
by an entire day headache free.
Power calculation
The sample calculation was run via an a priori sample
size calculator for Student’s t test. Cohen’s d was calcu-
lated on the basis of the results of (1) Mo’tamedi et al.
[14], concerning the Migraine Disability Assessment
scale score under acceptance and commitment therapy
and under the control condition (this is the only study
conducted in chronic migraine patients in which the Mi-
graine Disability Assessment scale [38], which is one of
our primary outcome measures, was used, although it
tests the efficacy of a stress-oriented psychotherapeutic
intervention which is different from WBT) and (2) Fava
et al. [26], which tests the efficacy of WBT in a sample
of patients with generalized anxiety disorder using, as
the outcome measure, the Psychological Well-being
scale [49], which is one of our secondary outcome mea-
sures. A Cohen’s d of 2.76 was obtained from Mo’tamedi
et al. [14] and a Cohen’s d of 1.38 was obtained from
Fava et al. [26]. Setting the power at 0.95 and the two-
sided alpha at 0.05, a minimum sample size of 5 per
group (two-tailed hypothesis) was obtained on the basis
of Mo’tamedi et al. [14] and a minimum sample size of
15 per group (two-tailed hypothesis) was obtained on
the basis of Fava et al. [26]. Thus, we will enroll 15 sub-
jects per group for a total of 30 subjects. In case of
drop-out, new enrolment will be run in order to have a
final sample size of 15 subjects per group who complete
the trial.
Ethics issues
No invasive procedure/test will be performed and no
drug administrated. During the study (from the
signature of informed consent to the study termination),
any clinical event will be registered in a case report
form. There are no documented side effects due to
WBT [19–21] or the control condition.
Discussion
The pharmacological treatment of chronic migraine has
achieved remarkable progress in recent years [52, 53].
However, significant issues persist in patients who do not
benefit from current drug treatments [54, 55] or for those
with limited access to innovative approaches, such as
anti-calcitonin gene-related peptide monoclonal anti-
bodies, due to financial constraints. Current evidence on
the efficacy of psychological interventions remains limited
and unsatisfactory [8–18]. This study proposes a method
aimed to empirically evaluate whether WBT provides a
beneficial effect in chronic migraine patients. In particular,
the present pilot study aims to test WBT versus a control
condition as a psychological intervention for chronic mi-
graine. The randomized trial represents a step towards the
management of chronic migraine by means of psycho-
logical interventions.
We acknowledge some limitations of the study. Inclu-
sion and exclusion criteria are proposed to maximize the
safety of enrolled patients. However, such restrictions may
reduce the possibility of generalization of results to the pa-
tient population with a more severe condition or those
with high degrees of comorbidity. In addition, the sample
size will not allow to test for potential differences in out-
come between different durations of the chronic migraine
or diverse levels of severity. Further, several key questions
remain and could be the object for future studies, includ-
ing whether, and at what size, differences in patient motiv-
ation or in the clinician–patient relationship may affect
the outcomes. Should results of this pilot exploratory trial
support our hypothesis, the next step will be a second trial
enrolling a larger number of chronic migraine patients
with a randomized and controlled multicentric design to
investigate efficacy and potential mediators of treatment
effects.
Trial status
Participant recruitment has not started.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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